The strongest independent predictor of SCC metastasis

DecisionDx-SCC provides an independent risk of metastasis score as well as identifies patients likely to benefit from adjuvant radiation therapy (ART).

New publication in Future Oncology confirms DecisionDx-SCC identifies high-risk SCC patients who benefit most from adjuvant radiation therapy

DecisionDx-SCC has now been independently validated to predict ART treatment benefit in two studies comprising over 1,300 patients. Together, these two studies by Ruiz et al. in Future Oncology (2024) and Arron et al. in the Red Journal (2024) represent the largest published population of ART-treated high-risk SCC patients. Results from this study provide a validation of the performance of the previously reported (Arron et al. Red Journal 2024) benefit of ART for Class 2B tumors and a lack of benefit for Class 1 tumors and was conducted using 423 tumors from 399 patients from Brigham Women’s Health (BWH) and Cleveland Clinic. Given the consistency of the results from two independent cohorts, DecisionDx-SCC can aid in ART decision-making for patients with high-risk SCC tumors.

Hear how Mohs surgeon, Desiree Ratner, MD, uses DecisionDx-SCC to optimize SCC treatment decisions including referrals to radiation oncology

   

Learn more about
DecisionDx-SCC